WELCOME to epgonline.org

Search the site for any medical term or simply browse by disease topic. Access all the information you need in one place, when you need it, how you want it and for free! 
 

Latest News

Added 23 hours ago Drug news

Data review of Phase III study of Macrilen (macimorelin) for the evaluation of growth hormone deficiency in adults. -Aeterna Zentaris Inc.

Aeterna Zentaris Inc. announced that, following a comprehensive review of data obtained from the confirmatory Phase III clinical trial of...

Added 3 days ago Drug news

Phase III trial of Inflectra (infliximab CT-P13) meets endpoint in Crohn’s disease- Pfizer and Celltrion Healthcare

Data announced by Pfizer and Celltrion Healthcare showed that for patients with moderate-to-severe Crohn’s disease (CD), treatment with Inflectra (infliximab...

Added 3 days ago Drug news

Tivantinib fails to meet endpoint in METIV-HCC Phase III trial for hepatocellular carcinoma.- ArQule Inc. + Daiichi Sankyo

ArQule, Inc.and Daiichi Sankyo announced that the METIV-HCC phase III study of tivantinib in hepatocellular carcinoma (HCC) did not meet...

View all news articles

Latest Clinical Trials

A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

The purpose of the study is to determine whether, in patients with moderate to severe plaque-type psoriasis, AIN457 administered subcutaneously reduces the severity of psoriasis symptoms and the extent...

Added 1 day ago

A Dose-Ranging And Efficacy Study of LY2439821 (An Anti-IL-17 Antibody) In Patients With Moderate-To-Severe Psoriasis

The safety of ixekizumab (LY2439821) and any side effects that might be associated with it....

Added 2 days ago

A 12-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients With Moderate to Severe Plaque Psoriasis With a Long-Term Extension Period

This study will assess the safety and efficacy of ixekizumab (LY2439821), compared to etanercept and placebo in participants with moderate to severe chronic plaque psoriasis.

Added 5 days ago

View all clinical trials

 

Latest Journal Abstracts

Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision.

Allergic rhinitis represents a global health problem affecting 10% to 20% of the population.

Added 17 minutes ago

Allergic rhinitis and its impact on asthma (ARIA) 2008.

Allergic rhinitis is a symptomatic disorder of the nose induced after allergen exposure by an immunoglobulin E (IgE)-mediated inflammation of the membranes lining the nose.

Added 28 minutes ago

Influence of comorbid conditions on asthma.

Various conditions such as rhinosinusitis, gastro-oesophageal reflux disease, psychological disturbances, chronic infections and obstructive sleep apnoea are often observed in asthmatic patients and may affect asthma control and outcomes.

Added 40 minutes ago

View all journal articles

Latest Guidelines

Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision.

Allergic rhinitis represents a global health problem affecting 10% to 20% of the population.

Added 9 minutes ago

Adalimumab for the treatment of adults with psoriasis

The severity of a person's psoriasis before and during treatment should be assessed by considering the redness, thickness and scaliness of the plaques, the area of the body involved, and how the condition...

Added 6 days ago

British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009

Psoriasis is a common, chronic inflammatory skin disease which typically follows a relapsing and remitting course, and is associated with joint disease in approximately 25% of patients.

Added 6 days ago

View all guidelines